Sean M. Clayton - 01 Mar 2023 Form 4 Insider Report for Horizon Therapeutics Public Ltd Co

Role: EVP, General Counsel
Signature: /s/ Patrick McIlvenny, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 01 Mar 2023
Net transactions value: -$775,911
Form type: 4
Filing time: 06 Mar 2023, 15:52:11 UTC
Previous filing: 06 Jan 2023
Next filing: 06 Oct 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HZNP	Ordinary Shares	Options Exercise		+14,129	+5064%		14,408	01 Mar 2023	Direct	F1, F2
transaction	HZNP	Ordinary Shares	Tax liability	$775,911	-7,032	-49%	$110.34	7,376	01 Mar 2023	Direct
holding	HZNP	Ordinary Shares						745	01 Mar 2023	See footnote	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HZNP	Restricted Stock Units	Options Exercise	$0	+14,129	+100%	$0.000000	28,258	01 Mar 2023	Ordinary shares	14,129		Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.
F2	Includes 279 ordinary shares of the Issuer acquired by the reporting person on December 1, 2022 pursuant to an employee stock purchase program.
F3	The shares are held by the Clayton Family Trust, of which the Reporting Person is the co-trustee and beneficiary.
F4	The shares subject to the restricted stock units vest 1/3rd annually on each anniversary of March 1, 2022.